ClinicalTrials.gov record
Terminated Phase 3 Interventional

A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease

ClinicalTrials.gov ID: NCT06307613

Public ClinicalTrials.gov record NCT06307613. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 17, 2026, 4:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efgartigimod PH20 SC Administered by Prefilled Syringe in Adult Participants With Thyroid Eye Disease

Study identification

NCT ID
NCT06307613
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
argenx
Industry
Enrollment
102 participants

Conditions and interventions

Interventions

  • Efgartigimod PH20 SC Combination Product
  • Placebo PH20 SC Other

Combination Product · Other

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 26, 2024
Primary completion
Dec 14, 2025
Completion
Feb 11, 2026
Last update posted
Mar 15, 2026

2024 – 2026

United States locations

U.S. sites
16
U.S. states
9
U.S. cities
16
Facility City State ZIP Site status
Thrive Health - Beverly Hills Beverly Hills California 90210
UCI Health - Gavin Herbert Eye Institute Irvine California 92697
University Of Southern California - Keck School Of Medicine Los Angeles California 90033
Silkiss Eye Surgery San Francisco California 94102
Advanced Research LLC Coral Springs Florida 33067
Levenson Eye Associates Jacksonville Florida 32204
Bascom Palmer Eye Institute Miami Florida 33136
University of South Florida (USF) Health - Morsani Center for Advanced Healthcare Tampa Florida 33612
University of Illinois Chicago Chicago Illinois 60612
Wilmer Eye Institute Baltimore Maryland 21205
University of Michigan Ann Arbour Michigan 48105
Moyes Eye Center - Northland Kansas City Missouri 64154
Quest Diagnostics - Mercy Smith Glynn Callaway Springfield Missouri 65807
Duke University Durham North Carolina 27705
Penn Medicine - Penn Presbyterian Medical Center - Scheie Eye Institute Philadelphia Pennsylvania 19104
West Virginia University Eye Institute Morgantown West Virginia 26506

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 61 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06307613, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 15, 2026 · Synced May 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06307613 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →